H S Tager
Overview
Explore the profile of H S Tager including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
86
Citations
1156
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nakagawa S, Tager H, Steiner D
Biochemistry
. 2000 Dec;
39(51):15826-35.
PMID: 11123908
An invariant residue, valine B12, is part of the insulin B-chain central alpha-helix (B9-B19), and its aliphatic side chain lies at the surface of the hydrophobic core of the insulin...
2.
Pittman 4th I, Nakagawa S, Tager H, Steiner D
Biochemistry
. 1997 Mar;
36(12):3430-7.
PMID: 9131992
[GlyB24]insulin is a novel insulin analog which maintains nearly full biological activity [Mirmira, R. G., & Tager, H. S. (1989) J. Biol. Chem. 264, 6349-6354] even though its structure, as...
3.
Pittman 4th I, Tager H
Biochemistry
. 1995 Aug;
34(33):10578-90.
PMID: 7654714
A conformational change, termed the T --> R transition, which can be detected by visible, circular dichoric, and fluorescence spectroscopy, occurs in native insulin and tryptophan substituted insulin analogs ([TrpB25]-,...
4.
Zhong P, Cara J, Tager H
Proc Natl Acad Sci U S A
. 1993 Dec;
90(24):11451-5.
PMID: 8265572
We have investigated by use of placental membranes the mechanisms through which insulin-like growth factor I (IGF-I) comes to be associated with its alpha 2 beta 2 receptor heterotetramer. Our...
5.
Nakagawa S, Johansen N, Madsen K, Schwartz T, Tager H
Int J Pept Protein Res
. 1993 Dec;
42(6):578-84.
PMID: 8307689
To evaluate more thoroughly the importance of main-chain structure and flexibility in ligand interactions with the insulin receptor, we undertook to synthesize analogues with reduced peptide bonds in the COOH-terminal...
6.
Nakagawa S, Tager H
Biochemistry
. 1993 Jul;
32(28):7237-43.
PMID: 8343513
We have investigated the effects of altering the disposition between the COOH-terminal B chain domain of insulin and the core of the insulin molecule on ligand interactions with the hepatocyte...
7.
Post S, Rubinstein P, Tager H
Proc Natl Acad Sci U S A
. 1993 Mar;
90(5):1662-6.
PMID: 8383321
We have investigated the mechanisms through which des-His1-[Glu9]glucagon amide functions as a peptide antagonist of the glucagon receptor/adenylyl cyclase system. Studies with radiolabeled peptides identified that (i) the antagonist bound...
8.
Schaffer L, Kjeldsen T, Andersen A, Wiberg F, Larsen U, Cara J, et al.
J Biol Chem
. 1993 Feb;
268(5):3044-7.
PMID: 8428981
We have examined, by use of a hybrid insulin/insulin-like growth factor-I analog and chimeric insulin/type I insulin-like growth factor receptors, the interplay between ligand and receptor structure in determining the...
9.
Post S, Miyazaki H, Tager H
J Biol Chem
. 1992 Dec;
267(36):25776-85.
PMID: 1334486
We have investigated (by use of intact and saponinpermeabilized canine hepatocytes) the roles of Mg2+ and guanyl nucleotides in regulating glucagon-receptor interactions. In contrast to intact cells, saponinpermeabilized hepatocytes bind...
10.
Nakagawa S, Tager H
Biochemistry
. 1992 Mar;
31(12):3204-14.
PMID: 1554705
In order to evaluate the cause of the greatly decreased receptor-binding potency of the naturally occurring mutant human insulin Insulin Wakayama ([LeuA3]insulin, 0.2% relative potency), we examined (by the semisynthesis...